Find Cabotegravir manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

VMF

NDC API

API REF. PRICE (USD/KG)

$
$ 0

MARKET PLACE

0

API

0

FDF

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

Health Canada Patents

DIGITAL CONTENT

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

GLOBAL SALES INFORMATION

US Medicaid

NA

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 1051375-10-0, Gsk1265744, Gsk744, Gsk-1265744, Gsk1265744a, S-265744
Molecular Formula
C19H17F2N3O5
Molecular Weight
405.4  g/mol
InChI Key
WCWSTNLSLKSJPK-LKFCYVNXSA-N
FDA UNII
HMH0132Z1Q

Cabotegravir
Cabotegravir, or GSK1265744, is an HIV-1 integrase inhibitor that is prescribed with the non-nucleoside reverse transcriptase inhibitor, [rilpivirine]. Early research into cabotegravir showed it had lower oral bioavailability than [dolutegravir]. The devlopment of cabotegravir was later developed to create a long acting monthly intramuscular injection. Cabotegravir was granted FDA approval on 21 January 2021.
Cabotegravir is a Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor. The mechanism of action of cabotegravir is as a HIV Integrase Inhibitor, and Organic Anion Transporter 1 Inhibitor, and Organic Anion Transporter 3 Inhibitor.
1 2D Structure

Cabotegravir

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
(3R,6S)-N-[(2,4-difluorophenyl)methyl]-10-hydroxy-6-methyl-8,11-dioxo-4-oxa-1,7-diazatricyclo[7.4.0.03,7]trideca-9,12-diene-12-carboxamide
2.1.2 InChI
InChI=1S/C19H17F2N3O5/c1-9-8-29-14-7-23-6-12(16(25)17(26)15(23)19(28)24(9)14)18(27)22-5-10-2-3-11(20)4-13(10)21/h2-4,6,9,14,26H,5,7-8H2,1H3,(H,22,27)/t9-,14+/m0/s1
2.1.3 InChI Key
WCWSTNLSLKSJPK-LKFCYVNXSA-N
2.1.4 Canonical SMILES
CC1COC2N1C(=O)C3=C(C(=O)C(=CN3C2)C(=O)NCC4=C(C=C(C=C4)F)F)O
2.1.5 Isomeric SMILES
C[C@H]1CO[C@H]2N1C(=O)C3=C(C(=O)C(=CN3C2)C(=O)NCC4=C(C=C(C=C4)F)F)O
2.2 Other Identifiers
2.2.1 UNII
HMH0132Z1Q
2.3 Synonyms
2.3.1 MeSH Synonyms

1. (3s,11ar)-n-((2,6-difluoropyridin-3-yl)methyl)-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro(1,3)oxazolo(3,2-a)pyrido(1,2-d)pyrazine-8-carboxamide

2. Apretude

3. Cabotegravir Extended-release Injectable Suspension

4. Cabotegravir Sodium

5. Gsk-1265744

6. Gsk-1265744a

7. Gsk-1265744b

8. Gsk1265744

9. Gsk1265744a

10. Gsk1265744b

11. Gsk744

12. N-((2,4-difluorophenyl)methyl)-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro(1,3)oxazolo(3,2-a)pyrido(1,2-d)pyrazine-8-carboxamide

13. S-265744

14. S-265744b

15. Sodium (3s,11ar)-8-(((2,4-difluorophenyl)methyl)carbamoyl)-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydrooxazolo(3,2-a)pyrido(1,2-d)pyrazin-6-olate

16. Vocabria

2.3.2 Depositor-Supplied Synonyms

1. 1051375-10-0

2. Gsk1265744

3. Gsk744

4. Gsk-1265744

5. Gsk1265744a

6. S-265744

7. Gsk744 Lap

8. Gsk-1265744a

9. Gsk744 La

10. Gsk 744

11. S/gsk1265744

12. Gsk 1265744

13. Cabotegravir (gsk744, Gsk1265744)

14. Gsk744 (s/gsk1265744)

15. Hmh0132z1q

16. (3s,11ar)-n-(2,4-difluorobenzyl)-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydrooxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide

17. Cab

18. (3s,11ar)-n-((2,4-difluorophenyl)methyl)-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydrooxazolo(3,2-a)pyrido(1,2-d)pyrazine-8-carboxamide

19. Unii-hmh0132z1q

20. Cabotegravir [usan:inn]

21. Cabotegravirum

22. 744 La

23. Cabotegravir [inn]

24. Cabotegravir [jan]

25. Cabotegravir [usan]

26. Schembl82803

27. Cabotegravir [who-dd]

28. Cabotegravir (jan/usan/inn)

29. Cabotegravir; Gsk1265744

30. Chembl2403238

31. Gtpl11386

32. Dtxsid50146982

33. Chebi:172944

34. Cabotegravir [orange Book]

35. Amy27899

36. Bcp08631

37. Ex-a2330

38. Bdbm50492496

39. Mfcd25976748

40. S7766

41. Zinc96927633

42. Cabenuva Component Cabotegravir

43. S/gsk-1265744

44. Cabenuva (cabotegravir + Rilpivirine)

45. Ccg-268708

46. Cs-5078

47. Db11751

48. Cabotegravir Component Of Cabenuva

49. Ncgc00386434-02

50. Ac-30895

51. As-61279

52. Hy-15592

53. S/gsk1265744; Gsk744

54. D10548

55. P14046

56. A902375

57. Q15411012

58. (3r,6s)-n-[(2,4-difluorophenyl)methyl]-10-hydroxy-6-methyl-8,11-dioxo-4-oxa-1,7-diazatricyclo[7.4.0.0?,?]trideca-9,12-diene-12-carboxamide

59. (3r,6s)-n-[(2,4-difluorophenyl)methyl]-10-hydroxy-6-methyl-8,11-dioxo-4-oxa-1,7-diazatricyclo[7.4.0.03,7]trideca-9,12-diene-12-carboxamide

60. (3s,11ar)-n-((2,6-difluoropyridin-3-yl)methyl)-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro(1,3)oxazolo(3,2-a)pyrido(1,2-d)pyrazine-8-carboxamide

61. (3s,11ar)-n-(2,4-difluorobenzyl)-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide

62. (3s,11ar)-n-[(2,4-difluorophenyl)methyl]-2,3,5,7,11,11a-hexahydro-6-hydroxy-3-methyl-5,7-dioxo-oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide

63. (3s,11ar)-n-[(2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,11,11a-tetrahydrooxazolo[[?]]pyrido[[?]]pyrazine-8-carboxamide

64. (3s,11ar)-n-[(2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide

65. 1264720-72-0

66. N-((2,4-difluorophenyl)methyl)-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro(1,3)oxazolo(3,2-a)pyrido(1,2-d)pyrazine-8-carboxamide

67. Oxazolo(3,2-a)pyrido(1,2-d)pyrazine-8-carboxamide, N-((2,4-difluorophenyl)methyl)-2,3,5,7,11,11a-hexahydro-6-hydroxy-3-methyl-5,7-dioxo-, (3s,11ar)-

2.4 Create Date
2011-12-26
3 Chemical and Physical Properties
Molecular Weight 405.4 g/mol
Molecular Formula C19H17F2N3O5
XLogP32.1
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count8
Rotatable Bond Count3
Exact Mass405.11362698 g/mol
Monoisotopic Mass405.11362698 g/mol
Topological Polar Surface Area99.2 Ų
Heavy Atom Count29
Formal Charge0
Complexity814
Isotope Atom Count0
Defined Atom Stereocenter Count2
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Indication

Oral cabotegravir is indicated in combination with rilpivirine for the short term treatment of HIV-1 in virologically suppressed adults with no history of treatment failure to assess tolerability of cabotegravir or who have missed an injected dose of cabotegravir. Intramuscular extended-release cabotegravir is indicated in combination with rilpivirine as a complete regimen for virologically suppressed adults with no history of treatment failure. The intramuscular form is meant to replace their current antiretroviral treatment.


Treatment of human immunodeficiency virus (HIV-1) infection


Vocabria tablets are indicated in combination with rilpivirine tablets for the short-term treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA < 50 copies/mL) on a stable antiretroviral regimen without present or past evidence of viral resistance to, and no prior virological failure with agents of the NNRTI and INI class for:

- oral lead in to assess tolerability of Vocabria and rilpivirine prior to administration of long acting cabotegravir injection plus long acting rilpivirine injection.

- oral therapy for adults who will miss planned dosing with cabotegravir injection plus rilpivirine injection.

Vocabria injection is indicated, in combination with rilpivirine injection, for the treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA < 50 copies/mL) on a stable antiretroviral regimen without present or past evidence of viral resistance to, and no prior virological failure with agents of the NNRTI and INI class.


Treatment of human immunodeficiency virus (HIV-1) infection


Prevention of human immunodeficiency virus (HIV-1) infection


5 Pharmacology and Biochemistry
5.1 Pharmacology

Cabotegravir is an inhibitor of HIV integrase, which reduces viral replication. It has a long duration of action as the oral tablet is given daily and the intramuscular suspension is given monthly. Patients should be counselled regarding the risk of hypersensitivity, hepatotoxicity, and depression.


5.2 MeSH Pharmacological Classification

HIV Integrase Inhibitors

Inhibitors of HIV INTEGRASE, an enzyme required for integration of viral DNA into cellular DNA. (See all compounds classified as HIV Integrase Inhibitors.)


5.3 FDA Pharmacological Classification
5.3.1 Active Moiety
CABOTEGRAVIR
5.3.2 FDA UNII
HMH0132Z1Q
5.3.3 Pharmacological Classes
Mechanisms of Action [MoA] - Organic Anion Transporter 3 Inhibitors
5.4 ATC Code

J05AX


J - Antiinfectives for systemic use

J05 - Antivirals for systemic use

J05A - Direct acting antivirals

J05AJ - Integrase inhibitors

J05AJ04 - Cabotegravir


5.5 Absorption, Distribution and Excretion

Absorption

Oral cabotegravir has a Tmax of 3 hours, reaches a Cmax of 8.0 g/mL, and has an AUC of 145 g\*h/mL. Intramuscular extended-release cabotegravir has a Tmax of 7 days, reaches a Cmax of 8.0 g/mL, and has an AUC of 1591 g\*h/mL.


Route of Elimination

An oral radiolabelled dose of cabotegravir is 58.5% recovered in the feces and 26.8% recovered in the urine.


Volume of Distribution

Data regarding the volume of distribution of cabotegravir is not readily available.


Clearance

Data regarding the clearance of cabotegravir is not readily available. Clearance in dogs was 0.34 mL/min/kg and in cynomolgus monkeys was 0.32 mL/min/kg.


5.6 Metabolism/Metabolites

Cabotegravir is O-glucuronidated to the M1 and M2 metabolites, with 67% of glucuronidation performed by UGT1A1, and 33% by UGT1A9.


5.7 Biological Half-Life

The mean half life of oral cabotegravir is 41 hours. The mean half life of intramuscular extended-release cabotegravir is 5.6-11.5 weeks.


5.8 Mechanism of Action

Cabotegravir binds to the active site of HIV integrase, preventing strand transfer of the viral genome into the host genome, and preventing replication of the virus.


API SUPPLIERS

read-more
read-more

01

ChemWerth Inc

U.S.A

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

Flag U.S.A
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Chemwerth Compnay Banner

02

Transo-Pharm USA LLC

U.S.A

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
PharmaVenue
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothTransoPharm USA works in the Sourcing and Management of Active Pharmaceutical Ingredients.

Flag U.S.A
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Transo Pharm USA Company Banner

03

Cipla

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

PharmaVenue
Not Confirmed
arrow

Cipla

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
PharmaVenue
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC arrow-down KDMF VMF Others AUDIT
blank

04

Guangdong Raffles PharmaTech Co Lt...

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

PharmaVenue
Not Confirmed
arrow

05

Hetero Drugs

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

PharmaVenue
Not Confirmed
arrow

Hetero Drugs

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
PharmaVenue
Not Confirmed
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

06

Maithri Drugs

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

PharmaVenue
Not Confirmed
arrow

07

Shenzhen HwaGen Pharmaceutical

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

PharmaVenue
Not Confirmed
arrow
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

USDMF

read-more
read-more

01

Cipla Ltd

India

USDMF

arrow
Pharma, Lab & Chemical Expo
Not Confirmed

01

Cipla Ltd

India
arrow
Pharma, Lab & Chemical Expo
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 37939

Submission : 2023-03-20

Status : Active

Type : II

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

KDMF

read-more
read-more

01

GSK

United Kingdom
Duphat
Not Confirmed
arrow

GSK

United Kingdom
arrow
Duphat
Not Confirmed

Cabotegravir

Registrant Name : GlaxoSmithKline Inc.

Registration Date : 2022-02-03

Registration Number : Su231-21-ND

Manufacturer Name : Glaxo Wellcome Manufacturing...

Manufacturer Address : 1 Pioneer Sector 1, 628413 Singapore

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

NDC API

read-more
read-more

01

Cipla Ltd.

India
Duphat
Not Confirmed
arrow

Cipla Ltd.

India
arrow
Duphat
Not Confirmed

CABOTEGRAVIR

NDC Package Code : 53104-7740

Start Marketing Date : 2023-11-16

End Marketing Date : 2024-12-31

Dosage Form (Strength) : POWDER (25kg/25kg)

Marketing Category : BULK INGREDIENT

blank

02

Duphat
Not Confirmed
arrow
arrow
Duphat
Not Confirmed

CABOTEGRAVIR

NDC Package Code : 52482-017

Start Marketing Date : 2019-12-23

End Marketing Date : 2024-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Suppliers

read-more
read-more

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

Flag U.S.A
Digital Content Digital Content

Cabotegravir

About the Company : Established in 1982, ChemWerth is a US-headquartered full-service generic active pharmaceutical ingredient (API) development and supply company. ChemWerth offers cGMP-quality APIs ...

Established in 1982, ChemWerth is a US-headquartered full-service generic active pharmaceutical ingredient (API) development and supply company. ChemWerth offers cGMP-quality APIs to regulated markets worldwide and has exclusive partnerships for new product development, compliance support and secure supply chain logistics. ChemWerth has access to over 500 APIs and more than 30 manufacturing facilities in the US, Europe, India and China. ChemWerth acts as a regulatory agent for over 25 FDA-approved facilities and sells more than 100 products. It has established its presence in 38 countries. In 2020, ChemWerth filed its 500th DMF with the FDA.
Chemwerth Compnay Banner

02

arrow
Pharma, Lab & Chemical Expo
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothTransoPharm USA works in the Sourcing and Management of Active Pharmaceutical Ingredients.

Flag U.S.A
Digital Content Digital Content

Cabotegravir

About the Company : Transo-Pharm, a fully licensed and certified distributor, specializes in pharmaceutical components for the health and veterinary industries. It offers support to clients throughout...

Transo-Pharm, a fully licensed and certified distributor, specializes in pharmaceutical components for the health and veterinary industries. It offers support to clients throughout the entire API life cycle, from product development through sales. Transo-Pharm serves as a sourcing and regulatory marketing agent for API manufacturers. It aids clients in establishing DMFs and provides GMP consulting. With a dedicated regulatory department, a warehouse, proprietary IPs for API processes, and partnerships with laboratories, Transo-Pharm offers a wide range of services. It operates from its offices in Shanghai, Hong Kong, Singapore, and the US.
Transo Pharm USA Company Banner

03

Pharma, Lab & Chemical Expo
Not Confirmed
arrow
arrow
Pharma, Lab & Chemical Expo
Not Confirmed

Cabotegravir

About the Company : Established in August 2011, Raffles PharmaTech is a high-tech enterprise that focus on development, manufacturing and sales of high-value added active pharmaceutical ingredients an...

Established in August 2011, Raffles PharmaTech is a high-tech enterprise that focus on development, manufacturing and sales of high-value added active pharmaceutical ingredients and intermediates. We are specialized in applying organic catalysts into the process development to lower cost, and to provide cost-effective product and service to customers. With our strong R&D capability and our proprietary organic catalysts, we provide low cost and high quality active pharmaceutical ingredients and intermediates to pharmaceutical companies. We also provide world standard process development, custom synthesis and manufacturing service.
blank

04

Hetero Drugs

India
Pharma, Lab & Chemical Expo
Not Confirmed
arrow

Hetero Drugs

India
arrow
Pharma, Lab & Chemical Expo
Not Confirmed

Cabotegravir

About the Company : Hetero is a research based global pharmaceutical company focused on development, manufacturing and marketing of Active Pharmaceutical Ingredients (APIs), Intermediate Chemicals & F...

Hetero is a research based global pharmaceutical company focused on development, manufacturing and marketing of Active Pharmaceutical Ingredients (APIs), Intermediate Chemicals & Finished Dosages. Ever since its establishment in 1993, Hetero showed a tradition of excellence and deep sense of commitment in developing cost effective processes to offer wide range of affordable drugs. Hetero is building on the strengths of vertical integration in discovery research, process chemistry, API manufacturing, formulation development and commercialization.
blank

05

Pharma, Lab & Chemical Expo
Not Confirmed
arrow
arrow
Pharma, Lab & Chemical Expo
Not Confirmed

Cabotegravir

About the Company : Maithri Drugs is one of India's fast-growing pharmaceutical companies. Maithri's strategic focus is on active pharma ingredients (APIs). The company is widely recognized for its ex...

Maithri Drugs is one of India's fast-growing pharmaceutical companies. Maithri's strategic focus is on active pharma ingredients (APIs). The company is widely recognized for its excellent research & development and aggressive growth strategies. Our 32 US DMFs and 9 CEPs in a short span attest to our R&D excellence. Maithri's manufacturing facility is located in Hyderabad. This facility is audited and approved by the US FDA. In addition, our facility is certified according to the standards of DCGI, WHO GMP, and ISO 9001:2015 We have a portfolio of 65 products and are continually expanding.
blank

06

Pharma, Lab & Chemical Expo
Not Confirmed
arrow
arrow
Pharma, Lab & Chemical Expo
Not Confirmed

Cabotegravir

About the Company : Shenzhen HwaGen Pharmaceutical Co., Ltd. (HwaGen Pharma) was founded in December of 2015 under the leadership of a “National 1000 Talents Program” expert. By leveraging its cor...

Shenzhen HwaGen Pharmaceutical Co., Ltd. (HwaGen Pharma) was founded in December of 2015 under the leadership of a “National 1000 Talents Program” expert. By leveraging its core competency in chiral synthesis, enzymatic catalysis and continuous flow micro reactor, HwaGen Pharmaceutical is dedicated to development and manufacturing of specialty and niche intermediates and APIs covering various therapeutic areas including oncology, antiviral and respiratory, delivering high value-added and affordable products for global pharmaceutical industry. Equipments for Analysis & Test include Tabletop NMR, LC-MS, GC, HPLC etc.
blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Drugs in Development

read-more
read-more

Details:

Apretude (cabotegravir) is an HIV-1 integrase strand transfer inhibitor indicated in at-risk adults and adolescents for PrEP to reduce risk of sexually acquired HIV-1 infection.


Lead Product(s): Cabotegravir

Therapeutic Area: Infections and Infectious Diseases Brand Name: Apretude

Study Phase: ApprovedProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 13, 2024

blank

01

ViiV Healthcare

United Kingdom
arrow
Duphat
Not Confirmed

ViiV Healthcare

United Kingdom
arrow
Duphat
Not Confirmed

Details : Apretude (cabotegravir) is an HIV-1 integrase strand transfer inhibitor indicated in at-risk adults and adolescents for PrEP to reduce risk of sexually acquired HIV-1 infection.

Brand Name : Apretude

Molecule Type : Small molecule

Upfront Cash : Not Applicable

May 13, 2024

blank

Details:

The UK MHRA approved two new formulations of cabotegravir (Apretude 30 mg & Apretude 600 mg) for preventing sexually transmitted HIV-1 infection in adults and adolescents.


Lead Product(s): Cabotegravir

Therapeutic Area: Infections and Infectious Diseases Brand Name: Apretude

Study Phase: ApprovedProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 04, 2024

blank

02

ViiV Healthcare

United Kingdom
arrow
Duphat
Not Confirmed

ViiV Healthcare

United Kingdom
arrow
Duphat
Not Confirmed

Details : The UK MHRA approved two new formulations of cabotegravir (Apretude 30 mg & Apretude 600 mg) for preventing sexually transmitted HIV-1 infection in adults and adolescents.

Brand Name : Apretude

Molecule Type : Small molecule

Upfront Cash : Not Applicable

May 04, 2024

blank

Details:

Edurant (rilpivirine) is an NNRTI for HIV-1 treatment, indicated for use with other antiretroviral agents in managing HIV-1 infection.


Lead Product(s): Rilpivirine,Cabotegravir

Therapeutic Area: Infections and Infectious Diseases Brand Name: Edurant

Study Phase: ApprovedProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 19, 2024

blank

03

Duphat
Not Confirmed
Duphat
Not Confirmed

Details : Edurant (rilpivirine) is an NNRTI for HIV-1 treatment, indicated for use with other antiretroviral agents in managing HIV-1 infection.

Brand Name : Edurant

Molecule Type : Small molecule

Upfront Cash : Not Applicable

March 19, 2024

blank

Details:

Cabenuva is a combination of cabotegravir, which inhibits HIV integrase by blocking retroviral DNA integration, and rilpivirine, which inhibits HIV-1 reverse transcriptase.


Lead Product(s): Cabotegravir,Rilpivirine

Therapeutic Area: Infections and Infectious Diseases Brand Name: Cabenuva

Study Phase: Phase IIIProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 06, 2024

blank

04

ViiV Healthcare

United Kingdom
arrow
Duphat
Not Confirmed

ViiV Healthcare

United Kingdom
arrow
Duphat
Not Confirmed

Details : Cabenuva is a combination of cabotegravir, which inhibits HIV integrase by blocking retroviral DNA integration, and rilpivirine, which inhibits HIV-1 reverse transcriptase.

Brand Name : Cabenuva

Molecule Type : Small molecule

Upfront Cash : Not Applicable

March 06, 2024

blank

Details:

Apretude (cabotegravir) is an integrase strand transfer inhibitor, long acting injection, which is being evaluated for the treatment of HIV-1 infection.


Lead Product(s): Cabotegravir

Therapeutic Area: Infections and Infectious Diseases Brand Name: Apretude

Study Phase: Phase IProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 04, 2024

blank

05

ViiV Healthcare

United Kingdom
arrow
Duphat
Not Confirmed

ViiV Healthcare

United Kingdom
arrow
Duphat
Not Confirmed

Details : Apretude (cabotegravir) is an integrase strand transfer inhibitor, long acting injection, which is being evaluated for the treatment of HIV-1 infection.

Brand Name : Apretude

Molecule Type : Small molecule

Upfront Cash : Not Applicable

March 04, 2024

blank

Details:

Cabenuva (cabotegravir + rilpivirine) is combination of HIV-1 integrase strand transfer inhibitor & RT inhibitor, being evaluated HIV-1 infection in adults.


Lead Product(s): Cabotegravir,Rilpivirine

Therapeutic Area: Infections and Infectious Diseases Brand Name: Cabenuva

Study Phase: Phase II/ Phase IIIProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 21, 2024

blank

06

ViiV Healthcare

United Kingdom
arrow
Duphat
Not Confirmed

ViiV Healthcare

United Kingdom
arrow
Duphat
Not Confirmed

Details : Cabenuva (cabotegravir + rilpivirine) is combination of HIV-1 integrase strand transfer inhibitor & RT inhibitor, being evaluated HIV-1 infection in adults.

Brand Name : Cabenuva

Molecule Type : Small molecule

Upfront Cash : Not Applicable

February 21, 2024

blank

Details:

Apretude (cabotegravir) is an HIV-1 integrase strand transfer inhibitor indicated in at-risk adults and adolescents for PrEP to reduce risk of sexually acquired HIV-1 infection.


Lead Product(s): Cabotegravir

Therapeutic Area: Infections and Infectious Diseases Brand Name: Apretude

Study Phase: ApprovedProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 10, 2024

blank

07

ViiV Healthcare

United Kingdom
arrow
Duphat
Not Confirmed

ViiV Healthcare

United Kingdom
arrow
Duphat
Not Confirmed

Details : Apretude (cabotegravir) is an HIV-1 integrase strand transfer inhibitor indicated in at-risk adults and adolescents for PrEP to reduce risk of sexually acquired HIV-1 infection.

Brand Name : Apretude

Molecule Type : Small molecule

Upfront Cash : Not Applicable

January 10, 2024

blank
  • Development Update

Details:

Vocabria (cabotegravir injection) is an integrase strand transfer inhibitor and used in combination with the Janssen Pharmaceutical Companies of Johnson & Johnson's Rekambys (rilpivirine long-acting injection) for the treatment of HIV-1 infection.


Lead Product(s): Cabotegravir,Rilpivirine

Therapeutic Area: Infections and Infectious Diseases Brand Name: Vocabria

Study Phase: ApprovedProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable October 26, 2023

blank

08

GSK

United Kingdom
arrow
Duphat
Not Confirmed

GSK

United Kingdom
arrow
Duphat
Not Confirmed

Details : Vocabria (cabotegravir injection) is an integrase strand transfer inhibitor and used in combination with the Janssen Pharmaceutical Companies of Johnson & Johnson's Rekambys (rilpivirine long-acting injection) for the treatment of HIV-1 infection.

Brand Name : Vocabria

Molecule Type : Small molecule

Upfront Cash : Not Applicable

October 26, 2023

blank
  • Development Update

Details:

Apretude (cabotegravir) long-acting for PrEP is an integrase strand transfer inhibitor (INSTI), which is indicated for the treatment of sexually acquired HIV-1 infection.


Lead Product(s): Cabotegravir

Therapeutic Area: Infections and Infectious Diseases Brand Name: Apretude

Study Phase: ApprovedProduct Type: Small molecule

Sponsor: ViiV Healthcare

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 19, 2023

blank

09

GSK

United Kingdom
arrow
Duphat
Not Confirmed

GSK

United Kingdom
arrow
Duphat
Not Confirmed

Details : Apretude (cabotegravir) long-acting for PrEP is an integrase strand transfer inhibitor (INSTI), which is indicated for the treatment of sexually acquired HIV-1 infection.

Brand Name : Apretude

Molecule Type : Small molecule

Upfront Cash : Not Applicable

September 19, 2023

blank

Details:

CAB LA (cabotegravir) long-acting for PrEP is an integrase strand transfer inhibitor (INSTI). INSTIs, like cabotegravir extended-release injectable suspension, inhibit HIV replication by preventing the viral DNA from integrating into the genetic material of human immune cells.


Lead Product(s): Cabotegravir

Therapeutic Area: Infections and Infectious Diseases Brand Name: CAB LA

Study Phase: ApprovedProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 24, 2023

blank

10

ViiV Healthcare

United Kingdom
arrow
Duphat
Not Confirmed

ViiV Healthcare

United Kingdom
arrow
Duphat
Not Confirmed

Details : CAB LA (cabotegravir) long-acting for PrEP is an integrase strand transfer inhibitor (INSTI). INSTIs, like cabotegravir extended-release injectable suspension, inhibit HIV replication by preventing the viral DNA from integrating into the genetic material...

Brand Name : CAB LA

Molecule Type : Small molecule

Upfront Cash : Not Applicable

July 24, 2023

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

ABOUT THIS PAGE

Cabotegravir Manufacturers

A Cabotegravir manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Cabotegravir, including repackagers and relabelers. The FDA regulates Cabotegravir manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Cabotegravir API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Cabotegravir manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

Cabotegravir Suppliers

A Cabotegravir supplier is an individual or a company that provides Cabotegravir active pharmaceutical ingredient (API) or Cabotegravir finished formulations upon request. The Cabotegravir suppliers may include Cabotegravir API manufacturers, exporters, distributors and traders.

click here to find a list of Cabotegravir suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

Cabotegravir USDMF

A Cabotegravir DMF (Drug Master File) is a document detailing the whole manufacturing process of Cabotegravir active pharmaceutical ingredient (API) in detail. Different forms of Cabotegravir DMFs exist exist since differing nations have different regulations, such as Cabotegravir USDMF, ASMF (EDMF), JDMF, CDMF, etc.

A Cabotegravir DMF submitted to regulatory agencies in the US is known as a USDMF. Cabotegravir USDMF includes data on Cabotegravir's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Cabotegravir USDMF is kept confidential to protect the manufacturer’s intellectual property.

click here to find a list of Cabotegravir suppliers with USDMF on PharmaCompass.

Cabotegravir KDMF

In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.

Pharmaceutical companies submit a Cabotegravir Drug Master File in Korea (Cabotegravir KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Cabotegravir. The MFDS reviews the Cabotegravir KDMF as part of the drug registration process and uses the information provided in the Cabotegravir KDMF to evaluate the safety and efficacy of the drug.

After submitting a Cabotegravir KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Cabotegravir API can apply through the Korea Drug Master File (KDMF).

click here to find a list of Cabotegravir suppliers with KDMF on PharmaCompass.

Cabotegravir NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Cabotegravir as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for Cabotegravir API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture Cabotegravir as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain Cabotegravir and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Cabotegravir NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of Cabotegravir suppliers with NDC on PharmaCompass.

Cabotegravir GMP

Cabotegravir Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Cabotegravir GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Cabotegravir GMP manufacturer or Cabotegravir GMP API supplier for your needs.

Cabotegravir CoA

A Cabotegravir CoA (Certificate of Analysis) is a formal document that attests to Cabotegravir's compliance with Cabotegravir specifications and serves as a tool for batch-level quality control.

Cabotegravir CoA mostly includes findings from lab analyses of a specific batch. For each Cabotegravir CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Cabotegravir may be tested according to a variety of international standards, such as European Pharmacopoeia (Cabotegravir EP), Cabotegravir JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Cabotegravir USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty